Impact of initiation of amikacin liposome inhalation suspension on hospitalizations and other healthcare resource utilization measures: a retrospective cohort study in real-world settings

BACKGROUND: Mycobacterium avium complex lung disease (MAC-LD) is an infection that is increasing in frequency, associated with substantial disease burden, and often refractory to treatment. Amikacin liposome inhalation suspension (ALIS) is the first therapy approved for refractory MAC-LD. In the CON...

Descripción completa

Detalles Bibliográficos
Autores principales: Aksamit, Timothy, Wu, Jasmanda, Hassan, Mariam, Achter, Emily, Chatterjee, Anjan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719199/
https://www.ncbi.nlm.nih.gov/pubmed/36463137
http://dx.doi.org/10.1186/s12890-022-02257-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719199/
https://www.ncbi.nlm.nih.gov/pubmed/36463137
http://dx.doi.org/10.1186/s12890-022-02257-8

Ejemplares similares